ARGX241220C210000
- 172.00
- 0.000.00%
argenx SE Newsroom
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?
Argenx to Present at Upcoming Investor Conferences
Argenx Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $706
Oppenheimer Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $675
Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $689
Jefferies Sticks to Their Buy Rating for Argenx Se (ARGX)
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $606 to $770
Express News | Argenx SE : Raymond James Raises Target Price to $770 From $688
Argenx Se's Promising Clinical Advancements and Positive ALKIVIA Study Results Underpin Buy Rating
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Sector Update: Health Care
Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data
Argenx SE Boosts Myositis Treatment Development
Argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Steritas Announces Collaboration With Argenx to Advance Evidence for Novel Steroid-sparing Therapeutics
Morgan Stanley Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $675